Genetically Engineered HSV-1 Phase 1 Study for the Treatment of Recurrent Malignant Glioma (M032-HSV-1)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02062827 |
|
Recruitment Status :
Recruiting
First Posted : February 14, 2014
Last Update Posted : May 12, 2020
|
Sponsor:
University of Alabama at Birmingham
Information provided by (Responsible Party):
James Markert, MD, University of Alabama at Birmingham
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Recruiting |
|---|---|
| Estimated Primary Completion Date : | September 2021 |
| Estimated Study Completion Date : | September 2023 |